SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma

Abstract

Differentiating between adenoid cystic carcinoma (AdCC) and polymorphous adenocarcinoma (PAC) can be difficult on small biopsies and cytologic specimens. As such, further characterization of their immunophenotype may aid in distinction. Previous studies have found AdCC to be SOX10+/GATA3 variable and PAC to be GATA3 negative. SOX10 expression in PAC has, as yet, not been established. We performed GATA3 and SOX10 immunohistochemistry on whole sections of 25 cases each of AdCC and PAC (including both classic PAC and the cribriform variant) to assess whether these markers are of diagnostic utility in distinguishing between these entities. SOX10 was found to be positive in 100% of PAC and AdCC whereas GATA 3 was immunoreactive in 45% of AdCCs and 20% of PAC. While this is the first series to compare SOX10 and GATA3 staining in these two tumor types, their frequent expression and similar staining patterns render them of limited value in discriminating between these neoplasms.

Microsecretory adenocarcinoma of the hard palate: A case report of a recently described entity

“…11 However, intraluminal secretions are uncommon in polymorphous carcinoma, which also carries PRKD1, −2 or −3 rearrangement or mutation. 12,13 In the current case, the tumor cells were positive for SOX10, as with adenoid cystic carcinoma and acinic cell carcinoma, 14,15 whereas tumor cells showed KIT negativity, unlike adenoid cystic carcinoma. 16,17 SOX10 has been reported as a marker of acinus and intercalated duct differentiation in salivary gland tumors.…”

Primary cutaneous Ewing sarcoma with diffuse S100/SOX10 positivity and pseudoalveolar pattern: An extraordinarily rare case highlighting a potential pitfall with significant repercussions

“…SOX10 is a transcription factor primarily known to be expressed in melanocytic and Schwann cells 28 . Thus, SOX10 has principally been explored as a marker for melanocytic and nerve sheath tumors of the skin and soft tissues, although it can also be seen in myoepithelial tumors and some carcinomas 28‐31 . Karachmandani et al 9 studied the expression of SOX10 and S100‐protein in soft tissue neoplasms including 14 cases of Ewing sarcoma, all of which were negative for SOX10.…”

“…28 Thus, SOX10 has principally been explored as a marker for melanocytic and nerve sheath tumors of the skin and soft tissues, although it can also be seen in myoepithelial tumors and some carcinomas. [28][29][30][31] Karachmandani et al 9 studied the expression of SOX10 and S100-protein in soft tissue neoplasms including 14 cases of Ewing sarcoma, all of which were negative for SOX10. Similarly, Miettinen et al 32 conducted a systematic analysis studying S100-protein and SOX10 expression in normal tissues, neural, neuroectodermal, epithelial, melanocytic, and mesenchymal tumors of which all 32 cases of Ewing sarcoma were negative for SOX10 expression.…”

GATA 3 Reactivity in Adenoid Cystic Carcinoma and Pleomorphic Adenoma of Salivary Glands

“…Among 150 patients, 43(86%) patients, 27(54%) patients, and 14(28%) patientsare confirmed to be GATA3 positive cases for normal ,PA, and ACC respectively.Schwartz et at (15) research demonstrate a wide types of salivary tumors, resulting 13/34 (38%) and 9/41 (22%) for PA andACCrespectively. Also, Adkins et al (17) is assessed GATA3 staining in ACC 45% (10/25).…”